GlassScriptPhysician profile
Shachar Peles
NPI 1568412930
$132,048.41
in general payments reported to CMS, 2019-2025
93 companies · $12K in 2025
The $12K reported for 2025 was more than what 82% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $14K · 2021: $8,670 · 2022: $12K · 2023: $13K · 2024: $19K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $23K · Food and Beverage: $12K · Consulting Fee: $7,763 · Travel and Lodging: $675 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $433 · Education: $74.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $22,820.00 |
| Food and Beverage | $11,748.27 |
| Consulting Fee | $7,762.50 |
| Travel and Lodging | $675.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $433.33 |
| Education | $74.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $31,873.35 | 2021-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $30,519.79 | 2019-2025 | Alunbrig, Vpriv, Ninlaro |
| Janssen Biotech, INC. | $23,111.49 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Celgene Corporation | $13,615.62 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Glaxosmithkline, LLC. | $7,125.01 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Verastem, INC. | $3,750.42 | 2019 | |
| Seagen INC. | $1,889.66 | 2019-2023 | Padcev, Tivdak, Tukysa |
| Pfizer INC. | $1,510.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,266.92 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Epizyme, INC. | $1,250.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,163.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,162.23 | 2019-2025 | Tagrisso, Enhertu, Lynparza |
| Adaptive Biotechnologies Corporation | $1,003.63 | 2019-2025 | Clonoseq |
| Genzyme Corporation | $973.70 | 2019-2025 | |
| Incyte Corporation | $842.75 | 2019-2025 | Jakafi, Niktimvo |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $827.73 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Geron Corporation | $825.20 | 2025 | Rytelo |
| Abbvie INC. | $649.62 | 2019-2025 | |
| Genentech USA, INC. | $637.96 | 2019-2025 | Phesgo, Tecentriq, Polivy |
| Daiichi Sankyo INC. | $604.53 | 2020-2025 | Enhertu, Datroway |
| Amgen INC. | $510.22 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Beigene USA, INC. | $477.73 | 2020-2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $409.40 | 2019-2025 | |
| Eisai INC. | $382.88 | 2019-2025 | |
| Puma Biotechnology, INC. | $348.79 | 2019-2025 | |
| Astellas Pharma US INC | $346.84 | 2019-2025 | Vyloy, Xtandi, Xospata |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.57 | 2019-2025 | |
| Blueprint Medicines Corporation | $311.81 | 2020 | |
| Emd Serono, INC. | $286.77 | 2022-2025 | Bavencio, Tepmetko |
| Alexion Pharmaceuticals, INC. | $250.82 | 2019-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $244.02 | 2022-2025 | Onivyde, Somatuline Depot, Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $235.55 | 2021-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $227.67 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $218.39 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $217.88 | 2023-2025 | Fotivda |
| Tersera Therapeutics LLC | $185.41 | 2021-2025 | Zoladex |
| Deciphera Pharmaceuticals INC. | $173.30 | 2021-2025 | Qinlock, Romvimza |
| Regeneron Healthcare Solutions, INC. | $172.46 | 2019-2025 | Libtayo |
| Dendreon Pharmaceuticals LLC | $160.67 | 2019-2024 | Provenge |
| Kite Pharma, INC. | $160.55 | 2020-2025 | Yescarta |
| Stemline Therapeutics INC. | $104.54 | 2023-2025 | Orserdu |
| Sobi, INC | $90.78 | 2022-2025 | |
| Legend Biotech USA INC. | $90.30 | 2024-2025 | Carvykti |
| Taiho Oncology, INC. | $88.59 | 2019-2023 | |
| Mirati Therapeutics, INC. | $81.02 | 2023-2024 | Krazati |
| Dova Pharmaceuticals | $72.02 | 2019-2021 | |
| Adc Therapeutics America, INC. | $66.55 | 2024-2025 | |
| Sirtex Medical INC | $65.49 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $64.23 | 2023-2024 | Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $57.80 | 2021-2025 | |
| Kyowa Kirin, INC. | $50.71 | 2019-2024 | Poteligeo |
| Heron Therapeutics, INC. | $48.19 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $47.76 | 2024-2025 | Myrisk |
| Clovis Oncology, INC. | $44.17 | 2019 | |
| Gilead Sciences, INC. | $43.49 | 2019-2021 | |
| Tg Therapeutics, INC. | $41.86 | 2021 | |
| Aurobindo Pharma USA, INC. | $40.08 | 2019-2020 | |
| Exelixis INC. | $40.06 | 2020-2023 | Cabometyx |
| Janssen Pharmaceuticals, INC | $39.10 | 2021-2025 | |
| Iovance Biotherapeutics, INC. | $38.12 | 2024-2025 | Amtagvi |
| Alnylam Pharmaceuticals INC. | $37.93 | 2022-2023 | Givlaari |
| G1 Therapeutics, INC. | $35.21 | 2023 | Cosela |
| Pharmaessentia USA Corporation | $34.42 | 2025 | Besremi |
| Agios Pharmaceuticals, INC. | $31.08 | 2020-2023 | Pyrukynd |
| Beone Medicines USA, INC. | $29.34 | 2025 | Tevimbra |
| Morphosys, US INC. | $28.87 | 2021 | |
| Pharmacosmos Therapeutics INC. | $28.84 | 2023 | Monoferric |
| Blue Earth Diagnostics | $28.46 | 2023 | |
| Janssen Scientific Affairs, LLC | $24.96 | 2019 | |
| Servier Pharmaceuticals LLC | $24.54 | 2024 | |
| Emmaus Medical, INC. | $23.09 | 2022 | |
| Delcath Systems | $21.26 | 2025 | Hepzato Kit |
| Shire North American Group INC | $19.86 | 2019 | |
| Recordati_rare_diseases_inc. | $19.75 | 2024 | Sylvant |
| Biocon Biologics INC | $19.45 | 2025 | Ogivri |
| Immunogen, INC. | $19.31 | 2023 | Elahere |
| Coherus Oncology, INC. | $19.21 | 2023 | |
| Tesaro, INC. | $18.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.09 | 2020 | |
| Partner Therapeutics, INC. | $17.09 | 2019 | |
| Advanced Accelerator Applications | $16.85 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.85 | 2025 | Vivimusta |
| Acrotech Biopharma INC. | $13.43 | 2022 | |
| Spectrum Pharmaceuticals INC. | $12.89 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.28 | 2019 | |
| Foundation Medicine, INC. | $11.73 | 2022 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,023.50 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shachar Peles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.